Výsledky vyhledávání - "Rebecca Z. Nielsen"

Efficacy and tolerability of vortioxetine versus agomelatine, categorized by previous treatment, in patients with major depressive disorder switched after an inadequate response

Autor: Marianne Dragheim, Brigitte Tonnoir, George I. Papakostas, Rebecca Z. Nielsen

Publikováno v: Journal of Psychiatric Research. 101:72-79

This study aimed to evaluate if efficacy and tolerability of switching to vortioxetine is independent of previous SSRI or SNRI treatment in patients who had been inadequately treated for their current major depressive episode. Patients from a double-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25cd056da8ec525c230c198788170a5d
https://doi.org/10.1016/j.jpsychires.2018.02.017

Zobrazit plný text záznamu

The impact of antidepressant treatments on family functioning in adults with major depressive disorder: a post hoc comparison of vortioxetine and agomelatine

Autor: Natalya Danchenko, Christophe Lançon, Clément François, Rebecca Z. Nielsen, Valerie Williams

Publikováno v: Current Medical Research and Opinion. 33:1057-1066

There is limited research on the impact of antidepressant treatment on family functioning. This study examines the impact of vortioxetine and agomelatine on family functioning using the Depression and Family Functioning Scale (DFFS).The DFFS was incl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0978eca4d0a444e9615ad45d78413e97
https://doi.org/10.1080/03007995.2017.1299701

Zobrazit plný text záznamu

A randomised, double‐blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin–noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine

Autor: Stuart Montgomery, Rebecca Z. Nielsen, Lis H. Poulsen, Lars Häggström

Publikováno v: Human Psychopharmacology

Objective This randomised, double-blind, 12-week study compared efficacy and tolerability of flexible-dose treatment with vortioxetine (10–20 mg/day) versus agomelatine (25–50 mg/day) in major depressive disorder patients with inadequate response

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b52652026f153d7379aef2796d80b9cb
https://doi.org/10.1002/hup.2424

Zobrazit plný text záznamu

The safety and tolerability of vortioxetine: analysis of data from randomised placebo-controlled trials and open-label extension studies

Autor: Ioana Florea, George G. Nomikos, Lambros Chrones, William Palo, Rebecca Z. Nielsen, David S. Baldwin, Elin Heldbo Reines

The safety and tolerability of vortioxetine in adults with major depressive disorder was assessed. Tolerability was based on the nature, incidence and severity of treatment-emergent adverse events (TEAEs) during acute (6/8) week treatment in 11 rando

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9fc597b19f3a614c0c43986bd0eeebf5
https://eprints.soton.ac.uk/385947/

Zobrazit plný text záznamu

The effect of Vortioxetine on family functioning in Adults with Major depressive Disorder

Autor: Valerie Williams, Clément François, Rebecca Z. Nielsen, Natalya Danchenko, Christophe Lançon

Publikováno v: Value in Health. 18:A124

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7821de40a30c8d8a3d084702543319bb
https://doi.org/10.1016/j.jval.2015.03.724

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání